Biotechnology company Pharming, which focuses on producing medicine using transgenic animals, booked a loss of €5m in the first three months of this year, compared with a loss of €3.7m in the same period of 2006.
The company has a cash balance of €26.2m, down from €31.1m in December. Pharming is still waiting for EU approval to market Rhucin, a new drug for the treatment of hereditary angioedema (which affects the immune system). It said it hopes to get the green light in the second half of this year.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation